| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Evra patch | Janssen Cilag | Laborex Kenya Eurapharma Ltd | 3 | Tablet | per tablet | KES 1,049 | |
| Logynon | Bayer Schering Pharma | Bayer East Africa Ltd. | 63 | Tablet | per tablet | KES 684 | |
| Marvelon | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 28 | Tablet | per tablet | KES 350 | |
| Mercilone | Schering-Plough (See also Essex Chemie) | Laborex Kenya Eurapharma Ltd | 28 | Tablet | per tablet | KES 567 | |
| Microgynon | Bayer Schering Pharma | Bayer East Africa Ltd. | 21 | Tablet | per tablet | KES 250 | |
| Sandostatin | Novartis Consumers | Harley's Limited | 20mg | 5 | Injection | KES 184,080.00 | |
| Sandostatin | Novartis Consumers | Harley's Limited | 0.05mg | 5 | Injection | per ml | KES 180,631 |
| Yasmin | Bayer Schering Pharma | Bayer East Africa Ltd. | 3mg/30mcg | 21 | Tablet | per tablet | KES 825.09 |
| Octride | Sun Pharmaceuticals Ltd | Sunpar Pharmaceuticals Ltd. | 50mg | 1 | Injection | per vial | KES 1,100.00 |
| Octreotide More info | |
|---|---|
| Mode Of Action | Somatostatin analogues such as octreotide suppresse secretions of: some anterior pituitary hormones, pancreatic endocrine and exocrine function, gastric acid, GI hormones, and serotonin. They also suppresse GI motility and splanchnic blood flow. |
| Drug Indication | Relief symptoms related to gastro-enteropancreatic endocrine tumour such as flushing, diarrhoea, and wheezing; acromegaly |
| Precautions | Diabetes mellitus; increased risk of cholelithiasis; renal function impairment; monitor of blood glucose, blood carotene level, faecal fat among others.Precautions: Diabetes mellitus; increased risk of cholelithiasis; renal function impairment; monitor of blood glucose, blood carotene level, faecal fat among others. |
| Contra-Indications | Sensitivity to the drug |
| Side Effects | Arrhythmias; constipation; diarrhoea; flatulence; nausea and vomiting; bradycardia; hyperglycemia; hypoglycemia; alopecia; dizziness; edema; headache; flushing of face; unusual weakness; fatigue; fever; acute pancreatitis. |
| Dosage | 20mg every 4 weeks for 3 months. Dosage may then be increased to 30mg every 4 wks or decreased to 10 mg 4 weeks. |
| Special Information | It is a synthetic polypeptide that is structurally and pharmacologically related to somatostatin (growth hormone release inhibiting factor). |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | ENDOCRINE DRUGS |
| Drug Sub-Category | Trophic hormones and other related products |